| 公司名称： |
上海波以尔化工有限公司 |
| 联系电话： |
Mr Qiu 86-21-50182298(Domestic Market)Miss Xu 86-21-50180596(Abroad Market) |
| 产品介绍： |
英文名称:A66;CCT128930
CAS:1166227-08-2
|
| 公司名称： |
上海佰世凯化学科技有限公司 |
| 联系电话： |
+86(0)21-20908456 |
| 产品介绍： |
英文名称:A66
CAS:1166227-08-2
备注：C13239 |
| 公司名称： |
济南精合医药科技有限公司 |
| 联系电话： |
+86 (531) 88811793；+86 (531) 88811783;+(0)18854807083; |
| 产品介绍： |
英文名称:A66
CAS:1166227-08-2
纯度：99% 包装信息：5Mg, 10Mg, 20Mg, 50Mg |
| 公司名称： |
大连美仑生物技术有限公司 |
| 联系电话： |
0411-66771943；0411-66771942 |
| 产品介绍： |
中文名称:A66,p110α抑制剂
英文名称:A66
CAS:1166227-08-2
纯度：>98%,BR 包装信息：5Mg,25Mg 备注：胆酸系列 |
|
| 中文名称: | A66 | | 中文同义词: | (2S)-N1-(2-叔丁基-4'-甲基[4,5'-联噻唑]-2'-基)-1,2-吡咯烷二甲酰胺;A66,P110Α抑制剂 | | 英文名称: | A66 | | 英文同义词: | CCT128930;(2S)-N1-[2-(tert-Butyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide;(2S)-N1-(5-(2-tert-butylthiazol-4-yl)-4-methylthiazol-2-yl)pyrrolidine-1,2-dicarboxamide;(2S)-N1-[2-(tert-Butyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide A 66 | | CAS号: | 1166227-08-2 | | 分子式: | C17H23N5O2S2 | | 分子量: | 0 | | EINECS号: | -0 | | 相关类别: | 信号转导通路激酶抑制剂;PI3K;PI3K/Akt/mTOR |
| 生物活性 | A66是一种有效的，特异性的p110α抑制剂，IC50为32 nM，作用于p110α比作用于其他I型PI3K亚型选择性高100倍以上。 | | 体外研究 | In addition to the wild-type p110α, A66 also potently inhibits the oncogenic forms of p110α such as p110α E545K and p110α H1047R with IC50 of 30 nM and 43 nM, respectively. Unlike PIK-75, A66 displays >100 fold selectivity for p110α over other class-I PI3K isoforms. Among the class-II PI3Ks, class-III PI3K and PI4Ks, A66 only exhibits limited cross-reactivity with the class-II PI3K PI3KC2β and the PI4Kβ isoform of PI4K with IC50 of 462 nM and 236 nM, respectively. A66 exhibits no inhibitory activity against other lipid kinases or the related kinases DNA-PK and mTOR. A66 has a higher degree of specificity compared with PIK-75 when tested at 10 μM against two large panels of 110 protein kinases and 318 kinases. Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and have high levels of p110α and class-Ia PI3K activity. A66 treatment at 0.7 μM induces a 75-80% reduction in focus formation by the highly transforming p85α iSH2 mutants KS459delN, DKRMN-S560del, and K379E, and reduces the phosphorylation of Akt on T308 by all p85 mutants. | | 体内研究 | A single dose of A66 at 100 mg/kg induces a profound reduction in the phosphorylation of Akt/PKB and p70 S6 kinase, but not of ERK, in SK-OV-3 tumour tissue in vivo at both 1 hour and 6 hours after dosing. A66 dosed at 100 mg/kg once daily (QD) for 21 days or 75 mg/kg twice daily (BID) for 16 days induces a significant delay in growth of SK-OV-3 xenografted tumors with average TGI of 45.9% and 29.9%, respectively, which is even greater than that induced by the well-established pan-PI3K inhibitor BEZ-235. QD dosing of A66 in the HCT-116 xenograft model also induces a significant reduction in tumour volume with TGI of 77.2%, but causes a non-significant reduction in tumor volume in the U87MG xenograft model. Administration of A66 at 10 mg/kg in male CD1 mice induces significant impairments in the ITT (insulin tolerance test) and GTT (glucose tolerance test), and an increase in glucose production during a PTT (pyruvate tolerance test), almost to the same level as the pan-PI3K inhibitors. | | 特征 | A66 is highly selective for p110α isoform. |
|